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Temporal changes in immune 
cell composition and cytokines 
in response to chemoradiation in 
rectal cancer
Yong Joon Lee1, Sat Byol Lee2,3, Suk Kyung Beak2,3, Yoon Dae Han3, Min Soo Cho3, Hyuk Hur3, 
Kang Young Lee3, Nam Kyu Kim3 & Byung Soh Min  2,3
We measured systemic changes in the immune response in 92 patients receiving preoperative 
chemoradiation therapy (CRT) and subsequent surgery for rectal cancer. The peripheral blood was 
sampled five times from the onset of CRT until surgery. Lymphocytes decreased continuously during 
CRT but increased after CRT. The increased lymphocyte population was predominantly CD8+ T 
lymphocytes, which accounted for a significantly larger proportion in patients without residual lymph 
node metastasis than in those with residual lymph node metastasis. Neutrophils and monocytes 
decreased during the initial two weeks of CRT but were maintained or increased afterwards. Neutrophil 
and monocyte counts were significantly lower in patients with a pCR (pathologic complete response) 
than in those without a pCR two weeks after CRT began but not at the initiation of CRT. All cytokines 
showed dramatic changes one month after the termination of CRT. Cytokines related to the antitumour 
immune response increased, and those related to tumour progression decreased. The predictive value 
of cytokines was not clear. In short, we observed that immune components in peripheral blood are 
affected by CRT and show dynamic changes over time. We identified biomarker candidates to predict 
the pathologic response in the future.
Chemoradiation therapy (CRT) is one of several effective options available for the treatment of solid tumours 
under various clinical settings. It is well known that CRT causes tumour regression through direct cytotoxicity 
and cytostaticity. However, accumulating evidence implies that CRT can also induce an antitumour immune 
response1–3. The immunomodulatory potential of radiotherapy was initially demonstrated through interpreta-
tion of the abscopal effect, which refers to the phenomenon of tumours shrinking outside the scope of localized 
radiotherapy. Thereafter, therapeutic approaches have focussed on harnessing the antitumour immune response 
by adjusting clinical radiation protocols. Additionally, it is well known that some chemotherapeutic agents can 
trigger the antitumour immune response by eliciting immunologic cell death4.
To date, several immunologic molecules associated with the therapeutic mechanisms of CRT have been sug-
gested as biomarkers that forecast therapeutic success or failure5–8. However, previous studies have questioned 
the reliability and reproducibility of these suggested biomarkers. Additionally, much remains to be learned about 
how an effective antitumour immune response is induced by chemoradiation. Hopefully, the recent emergence of 
immune checkpoint inhibitors and proven clinical effects to support their use in the treatment of various cancers 
will make it possible to enhance the efficacy of CRT by properly combining it with immunotherapy9,10.
In locally advanced rectal cancer (LARC), neoadjuvant CRT followed by radical surgery reduces locoregional 
recurrence and improves long-term survival11. Based on these advantages, CRT has become the standard ther-
apeutic modality for patients with LARC. However, the tumour response to CRT varies among patients: only 
approximately 20% of patients show a pathologic complete response (pCR), approximately 60% show a par-
tial response, and the remaining 20% do not respond to treatment12. Continuous efforts have been undertaken 
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to identify a highly predictive biomarker in order to provide other favourable therapeutic options for patients 
who are unresponsive to treatment. Additionally, we need to better understand the immunologic mechanism of 
chemoradiation to establish an optimal immunotherapeutic strategy.
Thus, we decided to explore the chronological changes in the systemic immune response during and after CRT 
in LARC patients. We measured the changes in immune cell composition and cytokines in peripheral blood that 
reflect the systemic immune response. We aimed to provide a comprehensive understanding of the immunologic 
mechanism of chemoradiation and to investigate potential candidate biomarkers as reliable predictors of the 
pathologic treatment response.
Results
Characteristics of patients and treatment schedule. The clinicopathologic characteristics of the 
patients are shown in Table 1. All patients received preoperative oral capecitabine-based chemotherapy and 
fractionated intensity-modulated radiotherapy (IMRT). The cumulative radiation dose at each time point, treat-
ment intervals, and blood sampling schedules are presented in Fig. 1. Radical surgeries were performed between 
four and twelve weeks after the termination of preoperative CRT. Approximately 20% of patients showed a pCR, 
Mandard grade 1, and almost 70% of patients were confirmed to have no residual lymph node metastasis upon 
pathological examination of surgical specimens.
Complete blood count (CBC) analysis and leukocyte composition. During the initial two weeks of 
CRT, total leukocyte, neutrophil, lymphocyte, and monocyte counts decreased (Fig. 2a). At one month after the 
onset of CRT, lymphocyte count further decreased as cumulative chemoradiation dose increased, but monocyte 
count increased; total leukocyte count and neutrophil count showed no significant changes. One month after the 
termination of CRT, total leukocyte count, neutrophil count and lymphocyte count, but not monocyte count, 
were increased. The change in leukocyte composition during and after CRT revealed that the lymphocyte to 
leukocyte ratio decreased during the course of CRT and began to recover after CRT was terminated (Fig. 3b). On 
the other hand, the neutrophil to leukocyte ratio and the monocyte to leukocyte ratio increased during CRT and 
decreased after CRT.
Predictive value of changes in leukocyte composition. We investigated the relationship between 
changes in leukocyte composition and the therapeutic response to CRT. There were no significant differences in 
N = 92
Age 57.35 ± 11.01
Sex
Male 66 (71.7%)
Female 26 (28.3%)
Histopathology
AWD/AMD 87 (94.6%)
APD 2 (2.2%)
Mucinous 3 (3.2%)
Clinical T Stage
cT2 7 (7.6%)
cT3 75 (81.5%)
cT4 10 (10.9%)
Clinical N Stage
negative 22 (23.9%)
positive 70 (76.1%)
CRM invasion
negative 27 (29.3%)
positive 65 (70.7%)
Mandard grade
1 (pCR) 19 (20.7%)
2 17 (18.5%)
3 44 (47.8%)
4 12 (13.0%)
ypN stage
yN0 63 (68.5%)
yN1 23 (25.0%)
yN2 6 (6.5%)
Table 1. Clinicopathological characteristics. Values are presented as the mean ± standard deviation or number 
(percentage). AWD = well-differentiated adenocarcinoma; AMD = moderately differentiated adenocarcinoma; 
APD = poorly differentiated adenocarcinoma; CRM = circumferential resection margin.
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lymphocyte count at any time point between patients with and without a pCR. At the onset of CRT, total leuko-
cyte, neutrophil, and monocyte counts were not significantly different between patients with and without a pCR. 
However, two weeks after initiating CRT, patients with a pCR had significantly lower total leukocyte, neutrophil, 
and monocyte counts than those without a pCR, and this trend continued (Fig. 3). Additionally, monocyte count 
significantly differed between patients with and without residual lymph node metastasis at two weeks after the 
onset of CRT, but there were no differences in the other cell counts (Supplementary Fig. S2).
Changes in T lymphocyte composition and their predictive value. Lymphocytes were further sub-
divided into CD4+ T lymphocyte cells (CD4+ T cells) and CD8+ T lymphocyte cells (CD8+ T cells) by flow 
cytometry analysis (Fig. 4a). The proportion of CD4+ T cells among total lymphocytes was relatively higher than 
that of CD8+ T cells during CRT, but after treatment was terminated, the proportion of CD8+ T cells increased 
and was similar to the proportion of CD4+ T cells (Fig. 4b). The ratio of CD8+ T cells to CD4+ T cells changed 
most dramatically from one month after CRT began to one month after CRT was terminated. The ratio of CD8 
T+ cells to CD4+ T cells was not significantly associated with the pCR rate (Fig. 4c), but patients with residual 
lymph node metastasis had a lower ratio of CD8+ T cells to CD4+ T cells than patients without residual lymph 
node metastasis one month after the termination of CRT.
Changes in peripheral cytokines and their predictive value. In the cytokine analysis, most 
INF-gamma values were below the range of the standard curve. Accordingly, we analysed the other five 
cytokines only. Although serum cytokine levels showed different patterns of change during and after CRT, all of 
the cytokines showed the most dramatic change from one month after CRT termination to just before surgery. 
Interleukin-12 (IL-12) levels decreased during CRT and began to recover one month after CRT was terminated. 
Monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein–1 alpha (MIP-1alpha) levels 
showed no significant change until one month after CRT was terminated, at which point they decreased signifi-
cantly. Latency-associated peptide (LAP) and stromal cell-derived factor-1 alpha (SDF-1alpha) levels decreased 
during CRT, increased for one month after the termination of CRT, and decreased again thereafter. The serum 
levels of MCP-1 and MIP-1 alpha two weeks after the onset of CRT were significantly higher in patients without 
residual lymph node metastasis than in those with residual lymph node metastasis (Supplementary Figs S3, S4).
Discussion
As more research shows that the antitumour immune response can be induced by chemotherapy and radiother-
apy, there is increasing interest in whether CRT-mediated changes in the immune response can be accurately 
measured and used to predict therapeutic response13. In this context, we tracked the chronological changes in 
peripheral immune cell components, especially T lymphocytes and cytokines, elicited by CRT in patients with 
LARC. Subsequently, we assessed whether these parameters could predict the pathologic treatment response to 
CRT.
The absolute numbers of leukocytes and subtypes, including neutrophils, lymphocytes, and monocytes, 
decreased two weeks after the onset of CRT (Fig. 2a). This phenomenon may be explained by the impact of 
radiation therapy (RT) on pelvic bone marrow suppression or the haematologic toxicity of oral capecitabine14,15. 
Interestingly, during CRT, only the lymphocyte count continuously decreased. This finding is consistent with 
that of previous studies: lymphocytes are the most sensitive peripheral blood cell to RT6,16,17. The nadir monocyte 
and neutrophil counts occurred two weeks after the onset of CRT, and afterwards, these counts increased or were 
maintained. From these findings, we postulated that monocytes and neutrophils are potentially more resistant 
to CRT than lymphocytes and may be associated with treatment response. Indeed, we observed that treatment 
response was inversely related to monocyte and neutrophil counts. The counts of monocytes, neutrophils, and 
total leukocytes, but not of lymphocytes, were significantly lower in patients with a pCR than in those without a 
pCR two weeks after CRT initiation but not at CRT initiation (Fig. 3). The unfavourable role of monocytes and 
neutrophils in the pathologic tumour response might be associated with the well-known immunosuppressive 
role of tumour-associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs), but additional 
studies on this relationship are needed to reach firm conclusions2.
Figure 1. Schematic diagram of treatment schedule and peripheral blood sampling schedule. IMRT = intensity-
modulated radiation therapy; Gy = greys; wks = weeks; CRT = chemoradiation therapy; OP = operation.
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Figure 2. Changes in leukocyte composition in response to CRT: complete blood count (CBC) analysis. (a) 
Absolute numbers of total leukocytes, neutrophils, lymphocytes, and monocytes in patients (n = 92) during and 
after CRT are indicated by dots. Repeated measures analysis of variance (ANOVA) demonstrated statistically 
significant effects of time; total leukocytes p < 0.001; neutrophils p < 0.001; lymphocytes p < 0.001; and monocytes 
p < 0.001. Two-tailed paired Student’s t-test was performed to analyse differences between time points. *p < 0.05; 
**p < 0.0083 (adjusted significance level by Bonferroni’s method); ***p < 0.001. (b) Changes in the ratios of 
neutrophils, monocytes, and lymphocytes to total leukocytes (percentage of total leukocytes). Data are presented 
as the means ± standard deviations (SDs). Onset = the onset of CRT; CRT2wks = 2 weeks after the onset of CRT; 
CRT1mo = 1 month after the onset of CRT; postCRT = 1 month after the termination of CRT.
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Numerous studies have aimed to discover reliable biomarkers predicting both long-term oncologic outcomes 
and the pathologic response to CRT in patients with LARC5,6,18,19. Previous studies showed that several parame-
ters, such as the neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), lympho-
cyte percentage among leukocytes, and platelet count, could be associated with tumour response to CRT6,17,20–22. 
However, the conclusions from these previous studies have been discrepant. The cutoff values of NLR and the 
time points at which NLR was measured have varied among studies, which evaluated a limited number of time 
points both pre-CRT and post-CRT6,21,22. Additionally, the timing and frequency of blood sampling varied mark-
edly among patients17,20. Notably, our study findings revealed that the differences in mean neutrophil and mono-
cyte counts between patients with and without a pCR were pronounced two weeks after the onset of CRT. These 
findings might indicate that immune components change dynamically in response to CRT, and therefore, evalu-
ating the immune response based on a single measurement would lead to flawed conclusions. Moreover, changes 
in neutrophil and monocyte counts during or after CRT, rather than at a single timepoint pre-CRT, could provide 
more valuable information for predicting pathologic tumour response.
The densities of CD8+ T cells and CD4+ T cells among tumour infiltrating lymphocytes (TILs) before CRT 
have been suggested to predict pathologic tumour response in rectal cancer23,24. Accordingly, we explored the 
changes in the proportions of CD8+ T cells and CD4+ T cells in peripheral blood. Interestingly, the propor-
tion of CD8+ T cells, known as the core cell component in antitumour immunity, was maintained without any 
apparent change and was lower than that of CD4+ T cells during CRT (Fig. 4b). However, after the termination 
of CRT, the proportion of CD8+ T cells markedly increased to that of CD4+ T cells. Unlike TILs, the relative 
ratio of CD8+ T cells to CD4+ T cells was not correlated with pathologic response. Instead, the magnitudes of 
the increase in the proportion of CD8+ T cells and the decrease in the proportion of CD4+ T cells after CRT ter-
mination were significantly associated with residual lymph node metastasis (Fig. 4c). This finding may be related 
Figure 3. Predictive value of leukocyte components regarding pathologic complete response (pCR). Patients 
were divided into two groups: patients with a pCR (n = 19) and patients without a pCR (n = 73). (a) Mean 
(±standard deviation, SD) total leukocyte counts of the two groups at each time point. Repeated measures 
ANOVA; time effect p < 0.001; group effect p = 0.031; time-group interaction p = 0.616. (b) Mean (±SD) 
neutrophil counts of the two groups at each time point. Repeated measures ANOVA; time effect p < 0.001; 
group effect p = 0.020; time-group interaction p = 0.610. (c) Mean (±SD) lymphocyte counts of the two 
groups at each time point. Repeated measures ANOVA; time effect p < 0.001; group effect p = 0.916; time-
group interaction p = 0.343. (d) Mean (±SD) monocyte counts of the two groups at each time point. Repeated 
measures ANOVA; time effect p < 0.001; group effect p = 0.012; time-group interaction p = 0.983. The 
intergroup differences were analysed using the two-tailed Welch’s t-test. *p < 0.05; **p < 0.0125 (adjusted 
significance level by Bonferroni’s method); ***p < 0.001. Onset = the onset of CRT; CRT2wks = 2 weeks after 
the onset of CRT; CRT1mo = 1 month after the onset of CRT; postCRT = 1 month after the termination of CRT.
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Figure 4. Changes in lymphocyte composition in response to CRT and the predictive value of these changes regarding 
pathological treatment response. (a) A flow cytometry plot shows the stratification of CD4+ T lymphocytes and 
CD8+ T lymphocytes. Lymphocytes were gated on a forward scatter by side scatter plot. Lymphocytes were subdivided 
into CD4+ T lymphocytes (CD3+CD4+) and CD8+ T lymphocytes (CD3+CD8+). (b) The proportions of CD8+ T 
lymphocytes and CD4+ T lymphocytes among total lymphocytes are presented in the left figure (n = 63). The ratio of 
CD8+ T lymphocytes to CD4+ T lymphocytes is presented in the right figure. Two-tailed paired Student’s t-test was 
used to analyse differences between two adjacent time points. *p < 0.05; **p < 0.0125 (adjusted significance level by 
Bonferroni’s method); ***p < 0.001. (c) The difference in the ratio of CD8+ T lymphocytes to CD4+ T lymphocytes 
between the pCR group (n = 15) and the non-pCR group (n = 49) is presented in the left figure. Repeated measures 
ANOVA; time effect p < 0.001; group effect p = 0.924; time-group interaction p = 0.838. The difference in the ratio of 
CD8+ T lymphocytes to CD4+ T lymphocytes between the ypN0 (no residual lymph node metastasis on pathological 
exam) group (n = 49) and the ypN1 or ypN2 (residual lymph node metastasis on pathological exam) group (n = 15) 
is presented in the right figure. Repeated measures ANOVA; time effect p < 0.001; group effect p = 0.07; time-group 
interaction p = 0.199. The intergroup differences were analysed using the two-tailed Welch’s t-test. *p < 0.05; **p < 0.01 
(adjusted significance level by Bonferroni’s method); ***p < 0.001. Data are presented as the mean ± standard 
deviation. Onset = the onset of CRT; CRT2wks = 2 weeks after the onset of CRT; CRT1mo = 1 month after the onset of 
CRT; postCRT = 1 month after the termination of CRT; preOP = just before surgery.
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7SCIENTIfIC REPORTS |  (2018) 8:7565  | DOI:10.1038/s41598-018-25970-z
to the typical roles of the lymph node, in which naïve T lymphocytes first contact specific antigen, prompting T 
lymphocyte proliferation and differentiation into effector T lymphocytes. We postulate that the mere quantitative 
measurement of peripheral T cells might not be enough to predict treatment response and that specific character-
ization of peripheral T cells, which more accurately reflects TILs, might be required.
To gain broad insight into the mechanisms that govern the systemic immune response, we investigated 
cytokines found to be related to chemoradiation or rectal cancer in previous studies25–30. The most striking find-
ing of the analysed data is that dramatic changes in all cytokines commonly occurred from 1 month after CRT 
termination to just before surgery. IL-12 participates in antigen presentation and the licensing process between 
type I CD4+ helper T cells and antigen presenting cells (APCs) and is regarded as one of the main effectors of 
antitumour immunity. IL-12 levels increased dramatically one month after CRT termination (Fig. 5). In contrast 
to IL-12, the other four cytokines decreased during the same period. MCP-1, MIP-1alpha, and SDF-1 reportedly 
mediate resistance to radiotherapy or are involved in tumour progression in rectal cancer and other malignan-
cies25,26,28. Additionally, TGF-beta, which was evaluated by measuring LAP levels in this study, is associated with 
poor oncologic outcomes in several cancers27. Therefore, we further identified the relationship between direc-
tional changes in cytokines and pathologic outcomes. While some cytokines measured at specific time points 
showed significant associations with pathologic tumour response, we could not clearly identify the predictive 
value of these relationships (Supplementary Figs S3, S4).
The current study has some limitations. We could not fully determine the diversity and heterogeneity of 
immune cells and cytokines to estimate and elucidate a precise immune response. Additionally, we only classified 
T lymphocytes as CD4+ T cells and CD8+ T cells. To better ascertain the role of lymphocytes, future research 
should use a more detailed classification of lymphocytes, including regulatory CD4+ T cells or cancer-specific 
CD8+ T cells, and functional stratification, such as the immune checkpoint expression or exhaustion profile (i.e., 
PD-1/CTLA-4 expression). Additionally, we should investigate more diverse cytokines concerning radiotherapy 
resistance or rectal cancer progression. Additionally, our study could not provide a complete explanation of the 
Figure 5. Changes in serum cytokine levels in response to CRT. Two-tailed paired Student’s t-test was used to 
analyse differences between two adjacent time points. *p < 0.05; **p < 0.0125 (adjusted significance level by 
Bonferroni’s method); ***p < 0.001. Data are presented as the mean ± standard deviation. 1 = the onset of CRT; 
2 = 2 weeks after the onset of CRT; 3 = 1 month after the onset of CRT; 4 = 1 month after the termination of 
CRT; 5 = just before surgery.
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mechanism by which peripheral immune cells and cytokines are affected by the local immune response mediated 
by TILs. Lastly, we interpreted statistical significance as p < 0.05 in this study, even if multiple comparisons were 
performed; we noted the p-value adjusted by Bonferroni’s method. Thus, there might be an inflated type I error 
rate.
Our study is of importance in that we sequentially measured temporal changes in the immune response in 
patients receiving the same standard treatment, CRT, for a specific disease, LARC. We observed that peripheral 
immune components were affected by CRT and changed dramatically over time. Additionally, we identified bio-
marker candidates to predict the pathologic response in the future and provided insights into therapeutic strate-
gies to improve CRT efficacy through immune modulation.
Methods
Patients. We prospectively enrolled 110 patients with locally advanced rectal cancer (LARC) who were sched-
uled to undergo preoperative chemoradiation therapy (CRT) and subsequent radical surgery and whose patho-
logic diagnosis was confirmed at Severance Hospital, Yonsei University College of Medicine between January 
2015 and November 2016. In this study, we excluded patients who did not meet the following eligibility criteria: 
(1) rectal adenocarcinoma or mucinous carcinoma, and (2) prior completion of preoperative CRT followed by 
surgery with a curative aim. Finally, a total of 92 patients were included in this study, excluding 15 patients who 
withdrew study consent, 1 patient whose final pathology was confirmed as prostate cancer, and 2 patients who 
decided to undergo chemotherapy only after metastasis was proven through close evaluation (Supplementary 
Fig. S1).
Clinicopathologic characteristics. Collected characteristics included age, sex, histopathological tumour 
characteristics, TNM stage, circumferential resection margin (CRM), primary tumour response to CRT, and 
residual lymph node stage (ypN). The 7th AJCC staging system was used to determine the TNM stage of the 
colorectal cancers. CRM involvement was evaluated by radiologists as invasion of the primary tumour into the 
proper mesorectal fascia. The primary tumour response to CRT was described by the tumour regression grading 
system suggested by Mandard et al.31.
Preoperative CRT, surgery, and pathological examination. Indications for preoperative CRT 
included primary tumour stage higher than T3 or positive lymph node status based on clinical and radiological 
examinations. Preoperative CRT comprised oral capecitabine chemotherapy (825 mg/m2 twice daily for 3 weeks) 
and pelvic irradiation (45 Gy in 25 fractions administered to the entire pelvis, followed by a 5.4 Gy boost to the 
gross tumour administered in 3 fractions over 6 weeks or 50 Gy in 25 fractions administered to the entire pelvis 
over 5 weeks). Curative resection, including total or partial mesorectal excision depending on tumour charac-
teristics, was performed within 12 weeks after CRT completion. Standardized pathological examination reports 
were completed for each case. The standard form required mandatory reporting of tumour differentiation, depth 
of tumour penetration, lymph node metastasis, CRM, lymphovascular invasion, and tumour regression grade.
Blood sampling. All patients underwent peripheral venous blood sampling at five different time points: (1) 
the onset of CRT (just before CRT or on the CRT start day), (2) two weeks after the onset of CRT (cumulative 
radiation dose of approximately 18–19.8 Gy), (3) one month after the onset of CRT (cumulative radiation dose of 
approximately 45–46.8 Gy), (4) one month after CRT termination, and (5) just before surgery. All blood samples 
were obtained within 7 days of the scheduled time point.
Complete blood count (CBC). Peripheral venous blood samples, except for those obtained just before sur-
gery, were analysed at the diagnostic test laboratory of our institution. White blood cell count, red blood cell 
count, platelet count and leukocyte differential count were calculated by automated cell counting machines or 
were manually counted by medical technologists using haemocytometers.
Lymphocyte isolation, antibodies, immunophenotyping, and flow cytometry. Peripheral blood 
mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Paque (GE Healthcare, Uppsala, Sweden) 
density gradient centrifugation. Purified PBMCs were cryopreserved until use. For immunophenotyping, cryo-
preserved PBMCs were thawed and stained with the following fluorochrome-conjugated antibodies for 30 min-
utes at 4 °C and then washed once: anti-CD3 (clone: SK7, fluorochrome: APC-Cy7), anti-CD4 (RPA-T4, FITC), 
and anti-CD8 (RPA-T8, Percp-Cy5.5) (all from BD Biosciences). The cryopreserved PBMC samples from all time 
points for the same patient were thawed and analysed on the same day. Flow cytometry analyses were performed 
on an LSR II instrument with FACSDiva software (BD Biosciences). Subsequently, the data were analysed with 
FlowJo software (Treestar).
Cytokine assay. Serum levels of interleukin-12 (IL-12), interferon gamma (INF-gamma), macrophage 
inflammatory protein-1 alpha (MIP-1alpha), monocyte chemotactic protein-1 (MCP-1), latency-associated 
peptide (LAP), and stromal cell-derived factor-1 alpha (SDF-1alpha) were determined by using customized 
ProcartaPlex multiplex immunoassays panels (Thermo Fisher Scientific, EPX060-19133-801) and a MAGPIX 
instrument (Thermo Fisher Scientific). Experiments were performed in duplicate, and the mean of values within 
the standard range is reported in this study.
Statistical analyses. Categorical data are presented as the frequencies and percentages. Continuous data are 
presented as the means and standard deviations. The intergroup differences were analysed using the two-tailed 
Welch’s t-test. The assumption of a normal distribution was evaluated by the Kolmogorov-Smirnov normality 
test or by comparing a histogram of the sample data to a normal probability curve and checking whether the 
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distribution graph had skewness < ±3 and kurtosis < ±7. Two-tailed paired Student’s t-test was used to compare 
matched samples. A p-value < 0.05 was considered significant, and confidence intervals (CIs) were calculated at 
the 95th percentile level. GraphPad Prism ver. 5 (GraphPad Software, La Jolla, Ca) was used for statistical analysis 
and to present the analysed data as graphs.
Ethics statement. All patients provided written informed consent after being given sufficient informa-
tion on the study protocol. The study procedures were in accordance with the Declaration of Helsinki and were 
approved by the Institutional Review Board of Severance Hospital (IRB Number: 4-2014-0054).
Data availability. The datasets generated and analysed in the current study are not publicly available due to 
patient privacy concerns but are available from the corresponding author on reasonable request.
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